Publisher
Springer Science and Business Media LLC
Reference81 articles.
1. McClements ME, MacLaren RE. Gene therapy for retinal disease. Transl Res. 2013;161(4):241–54. https://doi.org/10.1016/j.trsl.2012.12.007.
2. Athanasiou D, Aguila M, Aguila J, et al. The molecular and cellular basis of rhodopsin retinitis pigmentosa reveals potential strategies for therapy. Prog Retin Eye Res. 2018;62:1–23. https://doi.org/10.1016/j.preteyeres.2017.10.002.
3. Griciuc A, Aron L, Ueffing M. ER stress in retinal degeneration: a target for rational therapy? Trends Mol Med. 2011;17(8):442–51. https://doi.org/10.1016/j.molmed.2011.04.002.
4. Orlans DH, Barnard DAR, Patricio DMM, McClements DME, MacLaren PRE. Effect of AAV-mediated rhodopsin gene augmentation on retinal degeneration caused by the dominant P23H rhodopsin mutation in a knock-in murine model. Available from: www.iebertpub.com, p. hum.2020.008, May 2020, https://doi.org/10.1089/hum.2020.008.
5. Coave Therapeutics. Coave Therapeutics announces positive 12-months data from ongoing Phase I/II Clinical Trial of CTx-PDE6b in Patients with Retinitis Pigmentosa Caused by Bi-allelic Mutations in PDE6b. Available from: https://coavetx.com/coave-therapeutics-announces-positive-12-months-data-from-ongoing-phase-i-ii-clinical-trial-of-ctx-pde6b-in-patients-with-retinitis-pigmentosa-caused-by-bi-allelic-mutations-in-pde6b/. Accessed 6 Feb 2024.